Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2015-05-27Clinical Trial Update: Enhancing Synaptic Plasticity and Cognition in Schizophrenia [NA]
This clinical trial update reports on a completed study evaluating approaches to enhance synaptic plasticity in schizophrenia. It addresses …
-
CLINICAL_TRIALS trial_result · 2015-05-21Clinical Trial Update: A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder [Phase 4]
Phase 4 trial evaluating varenicline to prevent relapse to smoking in patients with schizophrenia or bipolar disorder; study completed with …
-
CLINICAL_TRIALS trial_result · 2015-05-21Clinical Trial Update: Extended Duration Nicotine Replacement Therapy and Bupropion in Smokers With Schizophrenia [Phase 4]
Phase 4 trial evaluating extended duration nicotine replacement therapy with bupropion in smokers with schizophrenia was terminated.
-
FDA approval · 2015-05-18FDA Approved: INVEGA HAFYERA — Original Application (Janssen Pharmaceuticals, Inc)
FDA approved INVEGA HAFYERA (paliperidone palmitate) from Janssen Pharmaceuticals in an Original Application. It is a long-acting injectable…
-
CLINICAL_TRIALS trial_result · 2015-05-15Clinical Trial Update: fMRI Cholinergic Mechanisms in Schizophrenia
Completed clinical trial assessing fMRI-based cholinergic mechanisms in schizophrenia; results were posted in 2015.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-05-07Clinical Trial Update: Peony-Glycyrrhiza Decoction (PGD) for Antipsychotic-induced Hyperprolactinemia in Patients With Schizophrenia [Phase 2]
Phase 2 clinical trial of Peony-Glycyrrhiza Decoction (PGD) for antipsychotic-induced hyperprolactinemia in schizophrenia has completed.
-
CLINICAL_TRIALS withdrawal · 2015-05-07Clinical Trial Update: Usability of a Website for People With Schizophrenia [NA]
The NIMH-sponsored clinical trial evaluating a website usability for people with schizophrenia has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2015-04-29Clinical Trial Update: Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia [Phase 2]
Phase 2 clinical trial evaluating talnetant versus placebo and risperidone in schizophrenia has completed.
-
CLINICAL_TRIALS trial_result · 2015-04-29Clinical Trial Update: A Brief Community Linkage Intervention for Dually Diagnosed Individuals [NA]
Completed clinical trial update on a community linkage intervention for individuals with dual diagnosis, including schizophrenia/psychotic d…
-
CLINICAL_TRIALS trial_result · 2015-04-29Clinical Trial Update: Optimizing Response in Psychosis Study [Phase 4]
Phase 4 clinical trial update for an Optimizing Response in Psychosis study indicates the trial was terminated with results posted in 2015.
-
CLINICAL_TRIALS research · 2015-04-28Clinical Trial Update: Morphological, Structural and Functional Neural Substrates of Quality of Life in Schizophrenia [NA]
Clinical trial update exploring neural substrates related to quality of life in people with schizophrenia.
-
CLINICAL_TRIALS withdrawal · 2015-04-28Clinical Trial Update: Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder [Phase 2]
Phase 2 study evaluating the Medical Information Device #1 (MIND1) for adherence, safety, and tolerability in schizophrenia or Bipolar I dis…
-
FDA approval · 2015-04-28FDA Approved: ARIPIPRAZOLE — Original Application (Alembic Pharmaceuticals Inc.)
FDA approved Alembic's original ANDA for aripiprazole, a generic version of the antipsychotic.
-
FDA approval · 2015-04-28FDA Approved: ARIPIPRAZOLE — Original Application (Exelan Pharmaceuticals, Inc.)
FDA approved a generic aripiprazole tablet under ANDA205064 for Exelan Pharmaceuticals, authorizing sale for the same indications as the bra…
-
CLINICAL_TRIALS research · 2015-04-27Clinical Trial Update: Pilot Study Using an NMDA Antagonist to Modulate Transcranial Direct Current Stimulation (tDCS) Effects on Sensory Discrimination [Phase 1, Phase 2]
A pilot Phase 1/2 study investigates whether an NMDA receptor antagonist can modulate the effects of transcranial direct current stimulation…
-
CLINICAL_TRIALS trial_result · 2015-04-24Clinical Trial Update: A Comparison of Long-acting Injectable Medications for Schizophrenia [Phase 4]
Phase 4 clinical trial update comparing long-acting injectable antipsychotics for schizophrenia and schizoaffective disorder; results were p…
-
FDA approval · 2015-04-23FDA Approved: RISPERIDONE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for risperidone from Aurobindo Pharma Limited under an ANDA.
-
CLINICAL_TRIALS trial_result · 2015-04-17Clinical Trial Update: 6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Participants With an Acute Exacerbation of Schizophrenia (P06124) [Phase 3]
Phase 3 trial comparing asenapine with placebo in adults with acute exacerbation of schizophrenia; the study was completed and results were …
-
CLINICAL_TRIALS research · 2015-04-17Clinical Trial Update: Relation of Catechol-O-methyltransferase (COMT) Genotype and Response to Cognitive Remediation Schizophrenia [NA]
A clinical trial update examining how COMT genotype affects response to cognitive remediation in individuals with chronic schizophrenia.
-
CLINICAL_TRIALS trial_result · 2015-04-17Clinical Trial Update: High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder [Phase 2, Phase 3]
This clinical trial update concerns high-dose quetiapine for treatment-refractory schizophrenia or schizoaffective disorder, spanning Phase …
-
CLINICAL_TRIALS trial_result · 2015-04-16Clinical Trial Update: Effectiveness of an Interactive Educational Website for Improving the Quality of Mental Health Care for People With Schizophrenia [NA]
This clinical trial update reports on the effectiveness of an interactive educational website aimed at improving quality of mental health ca…
-
CLINICAL_TRIALS trial_result · 2015-04-16Clinical Trial Update: CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
The VA-sponsored CSP #572 study on genetics of functional disability in schizophrenia and bipolar disorder has completed.
-
CLINICAL_TRIALS trial_result · 2015-04-15Clinical Trial Update: Equivalence of Generic Clozapine to Orally Dissolving Clozapine in Schizophrenia or Schizoaffective Disorder [Phase 4]
This document provides an update on a Phase 4 trial assessing whether a generic clozapine is equivalent to the orally dissolving Clozapine f…
-
CLINICAL_TRIALS trial_result · 2015-04-15Clinical Trial Update: Neurocognitive Training Integrated in OPUS Treatment Versus OPUS Treatment-as-usual [Phase 3]
A Phase 3 clinical trial comparing neurocognitive training integrated into OPUS treatment versus OPUS treatment-as-usual for schizophrenia h…
-
CLINICAL_TRIALS trial_result · 2015-04-14Clinical Trial Update: Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults [Phase 2]
Phase 2 clinical trial evaluating eltoprazine for cognitive impairment associated with schizophrenia in adults has completed. The study was …